2 messages
ABBV
AbbVie (ABBV): Q2 Beat, Guidance Raised, Pipeline Strength
Jul 31, 2025, 07:04 PM
Quarterly Post-Earnings Summary
AbbVie beat Q2 2025 expectations, raised guidance, and showcased strong pipeline momentum, offsetting Humira erosion and one-off charges, signaling resilient long-term growth.
ABBV
AbbVie (ABBV): Immunology Growth Drives Q2 Upside
Jul 29, 2025, 01:08 PM
Earnings Outlook
AbbVie is set for Q2 2025 earnings upside, driven by strong immunology and neuroscience growth, margin expansion, and disciplined working capital management.